BOSTON ( TheStreet) -- The S&P 500 has rebounded 5.4% so far in September, following a 4.7% drop last month. Those individuals who are underinvested in equities and hoping to catch the next wave of upside should consider the following 10 stocks, which receive top ratings from analysts and are expected to gain at least 50% in the months ahead. Warning: These stocks are risky. They are ordered by analysts' median projected return.

10. Visa ( V) is a credit-card company, operating an electronic payment network. Fiscal third-quarter net income declined 1.8% to $716 million, or 73 cents a share, as revenue grew 23%. The operating margin rose from 50% to 56%. Visa's stock trades at a forward earnings multiple of 14 and a book value multiple of 2 -- 12% and 72% discounts to IT services peer averages. It is expensive based on sales and cash flow per share. Of analysts covering Visa, 34, or 89%, advise purchasing its shares, three recommend holding and two suggest selling them.

9. CommScope ( CTV) makes coaxial and fiber-optic cable for communications companies. Second-quarter profit nearly tripled to $44 million, or 43 cents a share, as revenue ascended 6.9% to $838 million. The operating margin narrowed from 13% to 9.1%. CommScope's stock sells for a forward earnings multiple of 9.4, a book value multiple of 1.3, a sales multiple of 0.7 and a cash flow multiple of 5.7 -- 46%, 54%, 79% and 60% discounts to communications equipment peer averages. Roughly 92% of analysts rate the stock "buy" and 8% rate it "hold."

8. Delta Air Lines ( DAL) provides air transportation to passengers and cargo. Delta swung to a second-quarter profit of $467 million, or 55 cents a share, as revenue advanced 17% to $8.2 billion. The operating margin jumped from 0.8% to 11%. Delta's stock trades at a forward earnings multiple of 5.3 and a sales multiple of 0.3 -- 78% and 72% discounts to airline industry averages. It's expensive based on book value per share. Of researchers following Delta, 13, or 93%, advocate purchasing its shares and one advises holding them. None suggest selling Delta.

7. Gannett ( GCI) publishes newspapers, including USA Today, operates broadcasting stations and manages Web sites. Second-quarter profit nearly tripled to $195 million, or 73 cents a share, as revenue declined 1.6% to $1.4 billion. The operating margin rose from 15% to 20%. Gannett's stock sells for a trailing earnings multiple of 6.3, a forward earnings multiple of 5.6, a book value multiple of 1.7 and a cash flow multiple of 3.5 -- 71%, 78%, 52% and 77% discounts to media peer averages. Around 86% of analysts rate it "buy" and 14% rank it "hold."

6. Standard Microsystems ( SMSC) designs and sells silicon-based integrated circuits. Standard swung to a fiscal first-quarter profit of $630,000, or 3 cents a share, from a year-earlier loss. Revenue increased 56% to $97 million. The operating margin turned positive. Standard's stock trades at a forward earnings multiple of 9.8, a book value multiple of 1.2, a sales multiple of 1.3 and a cash flow multiple of 8.8 -- 19%, 78%, 59% and 34% discounts to semiconductor industry averages. All eight researchers following Standard Microsystems rate its stock "buy."

5. Orbital Sciences ( ORB) develops small and medium-class rockets and space systems for commercial and military customers. Second-quarter profit contracted 27% to $6.4 million, or 11 cents a share, as revenue expanded 25% to $338 million. The operating margin narrowed from 4.8% to 4.1%. Orbital's stock sells for a forward earnings multiple of 12, a book value multiple of 1.5 and a sales multiple of 0.7 -- 14%, 70% and 40% discounts to aerospace and defense industry averages. All eight analysts covering Orbital Sciences advise purchasing its shares.

4. Entegris ( ENTG) sells products to semiconductor, fuel-cell and life-sciences companies. It swung to a second-quarter profit of $18 million, or 14 cents a share, from a year-earlier loss. Revenue more than doubled. The operating margin climbed from the negatives to positive 16%. Entegris shares trade at a forward earnings multiple of 5.6, a book value multiple of 1.5 and a cash flow multiple of 8.4 -- 53%, 73% and 37% discounts to peer averages. Around 88% of analysts rate the stock "buy" and 12% rate it "hold."

3. Clinical Data ( CLDA) is a biotechnology company. It has several late-stage compounds, including Vilazodone for depression and Stedivaze for cardiac stress. It also sells genetic tests to determine drug response. Its fiscal first-quarter loss narrowed to $14 million, or 51 cents a share, from a loss of $15 million, or 88 cents, a year earlier. Revenue grew 48%. Clinical Data's stock is expensive based on all relative valuation metrics since the company is consistently unprofitable. Still, all six analysts following Clinical Data recommend purchasing its shares.

2. AMR ( AMR) owns American Airlines. The company's second-quarter loss narrowed 97% to $11 million, or 3 cents a share, as revenue gained 16% to $5.7 billion. The operating margin climbed from negative territory to positive 3.5%. AMR's stock trades at a forward earnings multiple of 7.3, a sales multiple of 0.1 and a cash flow multiple of 2 -- 70%, 90% and 57% discounts to airline peer averages. Of analysts following AMR, eight, or 57%, rate its stock "buy", five rate it "hold" and one ranks it "sell."

1. Micron Technology ( MU) makes semiconductors. Micron swung to a fiscal third-quarter profit of $939 million, or 92 cents a share, from a year-earlier loss. Revenue more than doubled to $2.3 billion. The operating margin climbed from negative territory to positive 12%. Micron's stock sells for a trailing earnings multiple of 4.7, a forward earnings multiple of 3.7, a book value multiple of 0.9 and a cash flow multiple of 2.8 -- 77%, 70%, 84% and 79% discounts to peer averages. Around 74% of analysts rate it "buy", 22% rate it "hold" and 4% rank it "sell."

-- Written by Jake Lynch in Boston.

RELATED STORIES:

Become a fan of TheStreet on Facebook.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Jim Cramer: We Are in a Bitter Adjustment Period

Jim Cramer: We Are in a Bitter Adjustment Period

Jim Cramer: We Are Off Fantasy Island and Not Going Back

Jim Cramer: We Are Off Fantasy Island and Not Going Back

Tech Stocks of Strength Amid the Chaos; Deciding When to Jump Back In -- ICYMI

Tech Stocks of Strength Amid the Chaos; Deciding When to Jump Back In -- ICYMI

Cramer: The Case For Diving Back In

Cramer: The Case For Diving Back In